Elotuzumab (Elotuzumab)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antineoplastic agents - monoclonal antibodies

Included in the formulation
  • Emplicity®
    lyophilizate d / infusion 
    Bristol-Myers Squibb Company     USA
    • АТХ:

    L.01.X.C.23   Elotuzumab

    Pharmacodynamics:

    The humanized IgG1 monoclonal antibody specifically binds to the SLAMF7 protein, which is expressed on the surface of myeloma cells, T-killers, plasma cells, monocytes, B cells and dendritic cells. SLAMF7 protein is absent on the surface of cells of healthy tissues.

    As a result of the binding of the SLAMF7 antigen, the anti-myeloma activity of immune cells increases, which leads to the destruction of myeloma cells.

    Pharmacokinetics:

    After intravenous infusion, the elimination half-life is about 82.4 hours.

    Metabolized in several ways, which include biodegradation of antibodies to low molecular weight peptides and amino acids. Elimination by the kidneys.

    Indications:

    It is used for the treatment of multiple myeloma, it is used in combination with lenalidomide and dexamethasone.

    ICD-10

    II.C81-C96.C90.0   Multiple myeloma

    Contraindications:

    Age to 18 years, hepatic insufficiency of medium and severe degree, individual intolerance.

    Carefully:

    Pregnancy and lactation, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. It is used with caution, in cases where the expected effect exceeds the risk to the fetus and newborn.

    Dosing and Administration:

    Intravenous, drip, with an initial rate of not more than 0.5 ml / min (with good tolerability, the infusion rate is increased, but it should not exceed 5 ml / min), 10 mg / kg at 1, 8, 15, 22 days of the first two cycles with a length of 28 days. Then on 1 and 15 days - 10 mg / kg of weight.

    The highest daily dose: 10 mg / kg.

    The highest single dose: 10 mg / kg.

    Side effects:

    Central and peripheral nervous system: chronic fatigue, headache, peripheral neuropathy.

    Respiratory system: cough, nasopharyngitis, pneumonia.

    Hemopoietic system: lymphocytopenia, leukopenia, thrombocytopenia.

    The cardiovascular system: arterial hypotension, bradycardia, chest pain, rarely - thromboembolism of the pulmonary artery.

    Digestive system: vomiting, anorexia, diarrhea.

    Musculoskeletal system: low back pain.

    Dermatological reactions: night sweats.

    Sense organs: cataract.

    urinary system: rarely - acute renal failure.

    Infusion reactions: hyperthermia, fever, chills.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic. Hemodialysis is ineffective.

    Interaction:

    Clinically significant interactions are not described.

    Special instructions:

    During treatment and a month after taking the drug it is recommended to use reliable methods of contraception.

    Instructions
    Up